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Apoptotic capacity (AC) in primary lymphocytes may be a marker for cancer susceptibility, and functional single nucleotide
polymorphisms(SNPs) in genes involved in apoptotic pathways may modulate cellular ACin response toDNA damage. To further
examine the correlation between apoptotic genotypes and phenotype, we genotyped 14 published SNPs in 11 apoptosis-related
genes (i.e., p53, Bcl-2, BAX, CASP9, DR4, Fas, FasL, CASP8, CASP10, CASP3,a n dCASP7) and assessed the AC in response to
benzo[a]pyrene-7,8-9,10-diol epoxide (BPDE) in cultured primary lymphocytes from 172 cancer-free subjects. We found that
among these 14 SNPs, R72P, intron 3 16-bp del/ins, and intron 6 G>Ai np53, −938C>Ai nBcl-2, and I522L in CASP10 were
signiﬁcant predictors of the BPDE-induced lymphocytic AC in single-locus analysis. In the combined analysis of the three p53
variants, we found that the individuals with the diplotypes carrying 0-1 copy of the common p53 R-del-G haplotype had higher
AC values compared to other genotypes. Although the study size may not have the statistical power to detect the role of other SNPs
in AC, our ﬁndings suggest that some SNPs in genes involved in the intrinsic apoptotic pathway may modulate lymphocytic AC
in response to BPDE exposure in the general population. Larger studies are needed to validate these ﬁndings for further studying
individual susceptibility to cancer and other apoptosis-related diseases.
Copyright © 2008 Zhibin Hu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Apoptosis, also known as the programmed cell death, is
a biological process that regulates physiological cell death
and plays an important role in the pathogenesis of a
variety of human diseases, including cancer [1]. Resistance
to apoptosis or reduced cellular apoptotic capacity (AC)
provides a survival advantage of the cells that may develop
into cancer cells, commonly seen in almost all types of
malignant diseases, and mutations in the genes involved in
apoptotic pathways are one of the molecular mechanisms
underlying carcinogenesis [2, 3] and cancer therapy [3, 4].
Benzo[a]pyrene (B[a]P) is a classic DNA-damaging car-
cinogen found in both tobacco smoke and the environment
as a result of fuel combustion [5]. Its bioactivated form,
benzo[a]pyrene diol epoxide (BPDE), can cause irreversible
damage to DNA by forming DNA adducts through covalent
binding or oxidation [6, 7]. If these adducts are unrepaired,
the cells will undergo apoptosis through activation of p53,
caspase-9 (CASP9), and caspase-3 (CASP3)[ 8, 9]. As a
pivotal regulator of cellular response to DNA damage, the
transcription factor encoded by the p53 tumor suppressor
gene has been clearly implicated in B[a]P-induced apoptosis,
and the levels of p53 protein expression has been correlated
with the levels of B[a]P-DNA adducts [8, 10]. Although
details of the signaling pathways that trigger apoptosis in
lymphocytes remain not fully understood, possible mecha-
nisms include transcriptional activation of the Bcl-2 family
members [11] and transcriptional upregulation of the death
receptors (DRs) [12, 13]. These complex proteins participate
in the activation of a sequential signaling that modulates
two main apoptotic pathways [4]. One is the intrinsic or
mitochondrial pathway, in which the stimuli of p53-Bcl-
2 pathway lead to the activation of CASP9 and release2 Journal of Cancer Epidemiology
of cytochrome c from the mitochondria [14]. The other,
referred to as the extrinsicor cytoplasmic pathway, involves
a group of proteins such as the DRs, the membrane-bound
Fas ligand, the Fas complexes, the Fas-associated death
domain, caspase-8 (CASP8), and caspase-10 (CASP10)[ 15,
16]. Activation of these two pathways initiates a common
downstream proteolytic cascade that involves CASP3 and
caspase-7 (CASP7) [4].
It is likely that the eﬃciency of these apoptotic path-
ways is genetically determined. Therefore, we hypothesized
that functional polymorphisms in genes involved in these
apoptotic pathways may modulate the AC phenotype, thus
contributing to individual variation in response to DNA
damage. To test this hypothesis, we selected 14 potentially
functional polymorphisms in 11 genes, that is, p53, Bcl-2,
BAX, and CASP9 involved in the intrinsic pathway;DR4, Fas,
FasL, CASP8,a n dCASP10 involved in the extrinsic pathway;
and CASP3 and CASP7, the eﬀective CASPs.W eg e n o t y p e d
for these 14 polymorphisms and assessed in vitro AC with
a terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick-end labeling (TUNEL) assay using BPDE-treated
primary lymphocytes from 172 subjects without cancer to
evaluate associations between their apoptotic genotypes and
the AC phenotype.
2. MATERIALS AND METHODS
2.1. Studypopulation
Subjects in the current study were the control subjects in
a molecular epidemiology study of lung cancer previously
described [17]. Brieﬂy, 172 subjects in this study were
randomlyselectedfromapoolofcancer-freecontrolsubjects
recruited from the Kelsey-Seybold Clinics, a large multispe-
cialty physician organization with several clinics throughout
the Houston metropolitan area. Each subject was scheduled
to be interviewed after a written informed consent was
obtained. After the interview, a venous blood sample of
about 20mL was collected from each subject. The research
protocol was approved by The University of Texas M. D.
AndersonCancerCenterandtheKelsey-SeyboldFoundation
institutional review boards.
2.2. SNPselection
We used the National Center for Biotechnology Information
(NCBI) dbSNP database (http://www.ncbi.nlm.nih.gov),
the National Institute of Environmental Health Sciences
(NIEHS) Environment Genome Project SNP databases
(http://egp.gs.washington.edu/directory.html and http://
www.genome.utah.edu/genesnps/) and literature search to
identify potentially functional variants in genes involved
in both intrinsic and extrinsic apoptotic pathways.
Polymorphisms with a minor allele frequency (MAF)
of ≥0.05 were included, if they may theoretically result in
amino acid changes (nonsynonymous SNP, nsSNP), located
at regulating regions such as promoters, or are reportedly
associated with known phenotypic eﬀects. Three reported
p53 SNPs were selected, including the well-known codon 72
SNP (R72P, G>C) and two intronic variants (a 16bp-del/ins
in intron 3 and a G-to-A transition in intron 6 because
their haplotypes were found to be functional [18]. Two
previously reported regulating SNPs in the promoters of
the Bcl-2 family members, Bcl-2 (−938C>A) and BAX
(−248G>A) [19, 20], were included. For the CASPs,w e
identiﬁed one nsSNP from each CASP8 (D302H, G>C),
CASP10 (I522L, A>T) [21], and CASP7 (D255E, C>G,
http://www.ncbi.nlm.nih.gov) and one of the two CASP9
nsSNPs in tight linkage disequilibrium (LD) (Q221R, G>A,
http://egp.gs.washington.edu/directory.html and [22].
Because no nsSNP was found in the coding region of CASP3,
we selected one common variant in its promoter region:
−1337C>G( http://www.genome.utah.edu/genesnps/). For
the death receptor genes, one nsSNP in DR4 and three
promoter SNPs in Fas and FasL were selected: T209R (C>G)
in DR4, –1377G>A and –670A>Gi nFas, and –844T>Ci n
FasL [23–26].
2.3. Genotyping
The genotyping methods used to distinguish the 14 selected
polymorphisms in 11 apoptosis-related genes are presented
in Table 1. Genotyping methods for seven of the poly-
morphisms were previously described: p53 R72P [27]),
p53 intron 3 16-bpdel/ins and intron 6 G>A[ 18], DR4
T209R [28], Fas –1377G>A and –670A>G[ 29], and FasL –
844T>C[30].Theremainingsevenpolymorphisms(i.e.,Bcl-
2 −938C>A,BAX −248G>A,CASP9 Q221R,CASP8D302H,
CASP10 I522L, CASP3 –1337C>G, and CASP7 D255E) were
detected by using a primer-introduced restriction analysis
(PIRA)—polymerase chain reaction (PCR) assay [31]a n d
summarized in Table 1. Genotyping was performed without
knowledge of the subjects’ phenotype; more than 10% of the
samples were randomly selected for conﬁrmation, and the
results were 100% concordant. For the seven self-designed
genotyping assays, PCR products containing each target
genotype were puriﬁed and the sequences were conﬁrmed by
direct sequencing.
2.4. Apoptosisassay
The apoptosis phenotype (i.e., apoptotic capacity [AC]) was
detected with the TUNEL assay previously described [32].
Brieﬂy, two parallel short-term cultures from each blood
sample were incubated at 37◦C without CO2 for 67 hours
before BPDE treatment. At the end of the incubation, one
of the two parallel cultures was treated with BPDE (98%
pure; Midwest Research Institute, Kansas City, Mo, USA)
at a ﬁnal concentration of 4μM. After an additional 5-
hour incubation, all cells were pelleted by centrifugation,
resuspended with lysis buﬀer (Human Erythrocyte Lysing
Kit, R&D Systems, Minneapolis, Minn, USA), ﬁxed for 1
hour, rinsed with phosphate-buﬀered saline, and ﬁnally
stored in 70% ethanol at –20◦C until used for the TUNEL
assay.
For the TUNEL assay, we used the APO-BRDU kit
(Phoenix Flow Systems, San Diego, Calif, USA) and followed
the manufacturer’s recommended protocol. The ratio of theZhibin Hu et al. 3
Table 1: Conditions of genotyping assays for the selected polymorphisms of some apoptotic genes.
Gene
Position,
base change,
and rs#
Genotyping
method
(a) Primer PCR
product Enzyme Gel band pattern
p53 R72P G>C
rs1042522 PCR-RFLP 5 -ATCTACAGTCCCCCTTGCCG-3  (sense)
5 -GCAACTGACCGTGCAAGTCA-3  (antisense) 296bp BstUI
G allele: 169bp,
127bp
C allele: 296bp
p53
Intron 3
16-bpins/del
rs17878362
PCR 5 -TGGGACTGACTTTCTGCTCTT-3  (sense)
5 -TCAAATCATCCATTGCTTGG-3  (antisense)
Del: 180bp
Ins: 196bp
p53
Intron 6
G>A
rs1625895
PCR-RFLP 5 -TGGCCATCTACAAGCAGTCA-3  (sense)
5 -TTGCACATCTCATGGGGTTA-3  (antisense) 404bp MspI
G allele: 336bp,
68bp
A allele: 404bp
Bcl-2
−938C>A
rs2279115
PIRA-PCR:
mismatch, antisense
primer +2 C-to-G
5 -TCCTGCCTTCATTTATCCAGCA-3  (sense)
5 -CCAGGAGAGAGACAGGGGACA-3  (antisense) 125bp NlaIII
C allele: 106bp,
19bp
A allele: 125bp
BAX
−248G>A
rs4645878
PIRA-PCR:
mismatch, sense
primer –2 G-to-C
5 -CATTAGAGCTGCGATTGGACCG-3  (sense)
5 -GCTCCCTCGGGAGGTTTGGT-3  (antisense) 109bp MspI
Ga l l e l e :8 9b p ,
20bp
A allele: 109bp
CASP9 Q221R G>A
rs1052576
PIRA-PCR:
mismatch, sense
primer –2 G-to-C
5 -GGCTTTGCTGGAGCTGGCCC-3  (sense)
5 -AGTACCCAATGCCTGCCCAGGG-3  (antisense) 121bp MspI
G allele: 102bp,
19bp
A allele: 121bp
DR4 T209R C>G
rs4871857 PCR-RFLP 5 -ATCCTCTGGGAACTCTGTGG-3  (sense)
5 -GGGGACAGGCAGATGGAC-3  (antisense) 300bp DraIII
C allele: 200bp,
100bp
G allele: 300bp
Fas
−1377G>A
rs2234767
PIRA-PCR:
mismatch, sense
primer –2 A-to-G
5 -TGTGTGCACAAGGCTGGCGC-3  (sense)
5 -TGCATCTGTCACTGCACTTACCACCA-3 
(antisense)
122bp BstUI
G allele: 104bp,
18bp
A allele: 122bp
Fas –670A>G
rs1800682 PCR-RFLP 5 -ATAGCTGGGGCTATGCGATT-3  (sense)
5 -CATTTGACTGGGCTGTCCAT-3  (antisense) 193bp ScrFI A allele: 193bp
G allele: 136bp,
57bp
FasL
−844T>C
rs763110
PIRA-PCR:
mismatch, sense
primer –7 A-to-C
5 -CAATGAAAATGAACACATTG-3  (sense)
5 -CCCACTTTAGAAATTAGATC-3  (antisense) 85bp DraIII
Ta l l e l e :6 6b p ,
19bp
Ga l l e l e :8 5b p
CASP8 D302H G>C
rs1045485
PIRA-PCR:
mismatch, sense
primer –2 A-to-G
5 -CATTTTGAGATCAAGCCCCGC-3  (sense)
5 -CCCTTGTCTCCATGGGAGAGGA-3  (antisense) 132bp BstUI
G allele: 112bp,
20bp
C allele: 132bp
CASP10 I522L A>T
rs13006529
PIRA-PCR:
mismatch, antisense
primer +4 A-to-T
5 -GAGTGGACAAACAGGGAACAAA-3  (sense)
5 -AGAACCAACAAAAACTCTCTGCAATA-3 
(antisense)
122bp SspI
Ta l l e l e :9 7b p ,
25bp
A allele: 122bp
CASP3
−1337C>G
rs1405937
PIRA-PCR:
mismatch, sense
primer –2 C-to-A
5 -ATAGGCGCAAGTGTTAGAAACAGGAT-3  (sense)
5 -CACCAACACATGTGAGCACGAC-3  (antisense) 112bp FokI C allele: 112bp
Ga l l e l e :7 6b p ,
36bp
CASP7 D255E C>G
rs2227310
PIRA-PCR:
mismatch, sense
primer –2 G-to-C
5 -CCTGGAGGAGCACGGAAAACA-3  (sense)
5 -TGGAGACCACACAGGGGATCTG-3  (antisense) 137bp PvuII
G allele: 115bp,
22bp
C allele: 137bp
(a)RFLP = restriction fragment length polymorphisme; PIRA = primer-introduced restriction analysis.
diﬀerence in the percentages of apoptotic cells in a subject’s
BPDE-treated and untreated cultures to the percentage of
apoptotic cells in the untreated culture was recorded as the
AC (AC% = [ACtreated-ACbaseline)/ACbaseline] × 100) [32].
2.5. Statisticalanalysis
DNA quality or quantity was insuﬃcient for genotyping
in 2 subjects; thus, the ﬁnal analysis included 170 persons.4 Journal of Cancer Epidemiology
Diﬀerences of the continuous AC measurements between
genotypes/diplotypes of apoptotic genes were evaluated by
using Student’s t-test. Trend test was performed by using
the general linear regression model with adjustment for age
and sex. We dichotomized the continuous phenotype mea-
surements by using the median (150%) as the cutoﬀ value
to obtain an almost equal low-AC subgroup (84 subjects)
and high-AC subgroup (86 subjects). Logistic regression
analyses were used to estimate theodds ratios (ORs) and
95% conﬁdence intervals (CIs) between combined genetic
variants and dichotomized AC phenotype with adjustment
for age and sex. Alleles/haplotypes associated with the lower
AC phenotype in individual polymorphism analysis were
termed as “at-risk” alleles hereinafter. We used the PHASE
2.0 program [33] to infer haplotype frequencies based on the
observed genotypes for each gene. Diplotype was the most
probable haplotype pair for each individual. The potential
gene-gene interaction was evaluated by logistic regression
analysis and tested by comparing the changes in deviance (–
2 log likelihood) between the models of main eﬀects with or
without the interaction term. All of the statistical analyses
were performed with statistical analysis system software
(v.9.1.3; SAS Institute, Inc., Cary, NC, USA).
3. RESULTS
The mean age (±SD, years) of the 170 study subjects
(119 males and 51 females) was 57.99 ± 12.10, and we
dichotomized age by using the cutoﬀ value of 60 years to
facilitate comparisons between age groups. No statistical
diﬀerence was found in the continuous AC measurements
between the subgroups according to age and sex (data not
shown). Table 2 shows the continuous AC measurements
by genotypes of the selected apoptotic genes. The observed
genotype frequencies were all consistent with those expected
fromtheHardy-Weinbergequilibrium(datanotshown).For
SNPs in genes involved in the intrinsic apoptotic pathway,
varianthomozygotesofp53intron316-bpins/ins,p53intron
6 AA, and Bcl-2 −938AA all had signiﬁcantly higher AC than
theircorrespondingwild-typehomozygotes(496.07±121.26
versus 204.22 ± 183.21 for p53 intron 3 16-bpdel/ins, P =
.027; 496.07 ± 121.26 versus 199.44 ± 179.10 for p53 intron
6G >A, P = .021, and 247.62±225.67 versus 164.06±154.89
for Bcl-2 −938C>A, P = .046). However, the signiﬁcant P
values for the trend of higher AC with increasing number of
the variant alleles were observed only for p53 R72P (.016)
and Bcl-2 −938C>A (.037) as assessed in the general linear
regression model with adjustment for age and sex (Table 2).
In contrast, only the variant homozygotes of CASP10 I522L
out of all SNPs in genes involved in the extrinsic apoptotic
pathway had signiﬁcantly lower AC (159.49 ± 171.44) than
the II homozygote (239.07 ± 205.18, P = .046) as well as a
signiﬁcant trend of lower AC with increasing number of the
variant alleles (P = .046).
Linkage disequilibrium (LD) analysis showed that the
three loci in p53 were in LD (r2 = 0.14, D  = 0.64 for R72P
and intron 3 16-bpdel/ins; r2 = 0.24, D  = 0.85 for R72P
and intron 6 G>A; and r2 = 0.60, D  = 0.79 for intron 3
16-bpdel/ins and intron 6 G>A). Therefore, we performed
haplotype/diplotypeinferenceusingthePHASE2.0program
based on the observed genotypes. Overall, three common
hapolotypes were derived (Table 3). The diplotype carrying
zero copy of the p53 R-del-G haplotype and the diplotype
carrying two copies of the p53 P-ins-A haplotype all had
signiﬁcantly higher AC (termed as “protective” hereinafter)
and the eﬀect of the R-del-G haplotype was in a dose-
response manner (P for trend: .016; Table 3).
4. DISCUSSION
In the genotype-phenotype analysis, we examined the role
of potentially functional variants in selected apoptotic
genes in the AC phenotype induced by BPDE treatment
in primary lymphocytes. We found that R72P, intron 3
16-bpdel/ins, intron 6 G>Ai np53, –938C>Ai nBcl-2,
and I522L in CASP10 may be predictors of AC, but the
eﬀects of the p53 variants might also be modulated by
its downstream genes involved in the intrinsic pathway.
To the best of our knowledge, this is the ﬁrst multigene
genotype-phenotype correlation analysis in relation to the
apoptotic pathways in primary lymphocytes at a population
level.
Because there is tissue speciﬁcity in response to car-
cinogen exposure, it would be ideal to compare the BPDE-
induced AC measurements among diﬀerent tissues of the
same person. However, few reported studies have addressed
this tissue speciﬁcity, nor did our study have such an
opportunity. It was reported that B[a]P-induced apoptosis
of murine Hepa1c1c7 cells was through CASP-9 activation
related with p53 accumulation and activation [8] and that
a decrease in the expression of Bcl-2 to Bax ratio was
another hallmark of the process [8, 34]. Although obtained
from diﬀerent cell types, these ﬁndings are consistent with
our current observations that genetic variants in the genes
involved in the intrinsic apoptotic pathway may play an
important role in the prediction of AC phenotype. The Bcl-2
family is a group of evolutionarily conserved pro- and anti-
apoptotic proteins that play a pivotal role in the regulation
ofthemitochondrial-mediated(intrinsic)apoptoticpathway
[35]. Bcl-2 inhibits apoptosis through heterodimerization
with proapoptotic members of the Bcl-2 family, such as
Bax and also through formation of channels that stabilize
the mitochondrial membrane [36]. Bcl-2 expression has
also been implicated in the pathogenesis of cancers [37,
38], and the expression of Bcl-2 to Bax ratio seems to
be important in determining both in vitro and in vivo
response to chemotherapeutic drugs [39]. Recently, variant
allele of Bcl-2 −938C>A was found to be associated with
reduced prostate cancer risk in Caucasians in a small case-
control study, possibly due to the elimination of an Sp1
binding site, a downregulation of Bcl-2 mRNA transcript
levels, and unregulated programmed cell death [40], which
is consistent with what we found in the current study
(the variant A allele carriers were associated with high-AC
phenotype that may help eliminating possible malignant
cells).
Our results on the p53 polymorphisms were not consis-
tent with published data. For example, the wild-type 72RZhibin Hu et al. 5
Table 2: Comparisons of mean BPDE-induced apoptosis capacity in apparently normal primary lymphocytes by the genotypes of selected
apoptotic genes.
Variable No. (%) AC (mean ± SD) P value
(a) P value
(b)
Intrinsic pathway
p53 R72P
RR 91 (53.5) 180.47 ±164.13 Ref.
RP 65 (38.2) 223.07 ±196.22 .143
PP 14 (8.2) 313.40 ±243.25 .067 .016
p53 intron 3
16-bpdel/del 134 (78.8) 204.22 ±183.21 Ref.
16-bpdel/ins 34 (20.0) 204.51 ±194.62 .993
16-bpins/ins 2 (1.2) 496.07 ±121.26 .027 .274
p53 intron 6
GG 135 (79.4) 199.44 ±179.10 Ref.
GA 33 (19.4) 224.07 ±209.17 0.495
AA 2 (1.2) 496.07 ±121.26 .021 .099
Bcl-2 −938C>A
CC 53 (31.2) 164.06 ±154.89 Ref.
CA 76 (44.7) 216.62 ±180.38 .087
AA 41 (24.1) 247.62 ±225.67 .046 .037
BAX –248G>A
GG 144 (84.7) 205.39 ±189.73 Ref.
GA 25 (14.7) 225.99 ±173.85 .613
AA 1 (0.6) 84.85 —
CASP9 Q221R
QQ 53 (31.2) 194.75 ±169.29 Ref.
QR 75 (44.1) 213.91 ±199.95 .571
RR 42 (24.7) 213.00 ±187.11 .620 .704
Extrinsic pathway
DR4 T209R
TT 52 (30.6) 179.61 ±179.86 Ref.
TR 75 (44.1) 229.67 ±206.45 .160
RR 43 (25.3) 203.39 ±155.49 .497 .485
Fas –1377G>A
GG 126 (74.1) 218.66 ±195.82 Ref.
GA 42 (24.7) 179.99 ±158.13 .248
AA 2 (1.2) 100.14 ±92.38 .396 .182
Fas –670A>G
AA 43 (25.3) 210.82 ±173.91 Ref.
GA 86 (50.6) 236.97 ±203.18 .472
GG 41 (24.1) 143.07 ±147.70 .058 .085
FasL –844T>C
CC 79 (46.5) 225.68 ±195.41 Ref.
CT 74 (43.5) 190.11 ±180.80 .245
TT 17 (10.0) 200.82 ±173.81 .629 .464
CASP8 D302H
DD 127 (74.7) 202.30 ±184.45 Ref.
DH 38 (22.4) 210.97 ±195.10 .802
HH 5 (2.9) 320.41 ±183.38 .162 .389
CASP10 I522L
II 54 (31.8) 239.07 ±205.18 Ref.
IL 74 (43.5) 212.19 ±177.84 .430
LL 42 (24.7) 159.49 ±171.44 .046 .0466 Journal of Cancer Epidemiology
Table 2: Continued.
Variable No. (%) AC (mean ± SD) P value
(a) P value
(b)
Eﬀective CASPs
CASP3 –1337C>G
CC 107 (62.9) 210.98 ±202.46 Ref.
CG 51 (30.0) 212.23 ±166.75 .970
GG 12 (7.1) 159.34 ±109.53 .388 .516
CASP7 D255E
DD 95 (55.9) 214.49 ±190.29 Ref.
DE 68 (40.0) 195.79 ±166.92 .516
EE 7 (4.1) 231.51 ±318.48 .829 .801
(a)Two-sided Student t-test.
(b)Trend test obtained from general linear regress model with adjustment for age and sex.
Table 3: Comparisons of mean BPDE-induced apoptosis capacity
in apparently normal primary lymphocytes by p53 diplotypes.
p53 diplotypes No. (%) AC (mean ± SD) P value
(a) P value
(b)
R-del-G
2 copies 81 (47.6) 177.57 ±159.94 Ref.
1 copy 74 (43.5) 220.39 ±197.21 .138
0 copy 15 (8.8) 307.90 ±235.37 .009 .016
R-ins-G
0 copy 116 (68.2) 190.05 ±174.57 Ref.
1 copy 49 (28.8) 238.99 ±197.24 .116
2 copies 5 (2.9) 310.86 ±311.47 .146 .094
P-ins-A
0 copy 143 (84.1) 202.33 ±179.92 Ref.
1 copy 25 (14.7) 215.43 ±215.45 .745
2 copies 2 (1.2) 496.07 ±121.26 .023 .154
(a)Two-sided Student t-test.
(b)Trendtestobtainedfromgenerallinearregressmodelwithadjustmentfor
age and sex.
allele was found to be associated with an increased ability
to induce apoptosis in response to radiation or cytotoxic
drugs [18, 41, 42]. However, other data suggested that the
72P allele had a stronger transcription eﬀect in response
to DNA damage, leading to enhanced apoptotic phenotype
[43]. These previous studies were mainly based on assays
with cell lines [18, 41]a n ds u ﬀered with a limited sample
size [18, 41, 42]. Most importantly, no previous study
took into account other coexisting polymorphisms in the
genes involved in the intrinsic pathway, which may play an
important role in the B[a]P-induced apoptosis [8]. In the
present study with apparently normal primary lymphocytes,
we found that all minor variant alleles of the three p53
polymorphisms were associated with a higher AC phenotype
and that the overall eﬀects on the AC phenotype appeared
to be aﬀected by the CASP9 Q221R polymorphism, but the
interaction between polymorphisms of p53 and CASP9 was
only borderline signiﬁcant due to a limited study power.
However, our ﬁndings of this intrinsic apoptotic pathway in
lymphocytes may be relevant to other types of tissue as well
because this kind of induced apoptosis in lymphocytes may
be inheritable [44]. Thus these results, although preliminary,
need to be substantiated in larger studies.
Previous ﬁnding on the CASP10 I522L polymorphism
from a large breast cancer study showed that the variant
LL genotype was associated with a borderline signiﬁcant
1.30-fold increased cancer risk compared with the wild-type
II homozygote [21], which is consistent with the notion
that the LL homozygote contributes to a diminished AC.
However, the role of the extrinsic pathway (or only CASP10)
in B[a]P-induced apoptosis was not obvious in the present
study, which needs further evaluation.
In conclusion, this proof-of-principle study of genotype-
phenotype correlation provides evidence that potentially
functional polymorphisms in the core genes of the apoptotic
pathways may have a role in regulating the apoptotic
response to carcinogen exposure, at least in primary lym-
phocytes, although there is tissue speciﬁcity in response
to exposure to carcinogens. Such a modiﬁcation of host
carcinogen-induced AC in primary lymphocytes may con-
tribute to variation in individual susceptibility to cancer
in the general population. Although this study may be
limited due to small sample size, multiple tests, and lack
of repeated AC measurements for the same individuals, the
ﬁndings, if validated in more rigorously designed and larger
studies, should facilitate the design of future studies aimed
at identifying subpopulations at risk of cancer and other
apoptosis-related diseases.
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